Zhaoke Ophthalmology Limited (6622) Announces Results of Global Offering
EQS News / 04/28/2021 / 22:01 UTC + 8
Zhaoke Ophthalmology(6622) Announces the results of its global offering
Final offer price determined at HK $16.80 per share of the offer
Hong Kong Stock Exchange Main Board Listing April 29 2021
[April 28, 2021, Hong Kong] Zhaoke Ophthalmology Limited (“Zhaoke Ophthalmology” or the “Company”; stock code: 6622), an ophthalmic pharmaceutical company dedicated to the research, development and commercialization of therapies addressing significant unmet medical needs, announced its bid price and the award results of its global bid. The Company’s shares will begin trading on the Main Board of the Hong Kong Stock Exchange Limited (“Hong Kong Stock Exchange”) on April 29, 2021 (Thursday) at 9:00 am, with stock code 6622 in lots of 500 shares each.
The Hong Kong Offer Shares initially offered were over-subscribed with a subscription rate of approximately more than 56 of the 12,357,000 Shares offered in Hong Kong initially available for subscription. The Offered Shares initially offered as part of the International Offer were also slightly oversubscribed with a subscription rate of approximately 5.3 of the 111,210,500 Offered International Shares initially available for subscription. In the meantime, in accordance with the VSornate stone Iinvestment Athe recognition that the company has entered into with the investor Cornerstones, Cornerstone Investors have subscribed to 25,461,000 offer shares, representing approximately 20.60% of the number of shares offered as part of the global offer, assuming the over-allotment option is not exercised. Please refer to the section entitled “Cornerstone Investors” in the Prospectus for further details regarding Cornerstone Investors.
Zhaoke Ophthalmology Final Offer Price has been determined at HK $ 16.80 on the part of the supply. The net proceeds to be received by the Company are estimated to be approximately HK $ 1,941.6 million under the Global Offering (after deduction of subscription commissions and other registration-related costs paid or payable by the Company and before any exercise of the over-allotment option). The net proceeds will be used to fund the clinical development and commercialization of our core products, fund ongoing research and development activities as well as the commercialization of other drug candidates in our pipeline, complete the expansion of the production line of our Nansha manufacturing facility in anticipation of our product launches in the coming years and funding business development activities and drug pipeline expansion.
Goldman Sachs (Asia) LLC and Jefferies Hong Kong Limited are the Co-Sponsors, Co-Representatives, Global Co-Coordinators, Co-Bookrunners and Joint Leaders.
Dr Li Xiaoyi, Chairman of the Board, Executive Director and CEO of Zhaoke Ophthalmology, said, “We are very grateful for the support and attention of all investors. Satisfactory share subscription reflects investor confidence in the biopharmaceutical industry and our business and outlook. Being listed on the Main Board of the Hong Kong Stock Exchange is not only an important step in the development of the company, but also provides sufficient funds for the long-term development of the company. Looking to the future, the company aims to root deeply in the ophthalmic pharmaceutical industry, seize market opportunities, actively improve our core competitiveness, take full advantage of the unique international financing platform, as well as our competitive advantages, with the aim of becoming a leader in China and neighboring ASEAN countries, to further enhance capabilities in the future, to maximize shareholder value. “
04/28/2021 Distribution of a marketing press release, sent by EQS Group.
The issuer is solely responsible for the content of this advertisement.
Media archive at www.todayir.com